子宮頸がん治療薬の世界市場2015-2019

【英語タイトル】Global Cervical Cancer Market 2015-2019

Technavioが出版した調査資料(IRTNTR7066)・商品コード:IRTNTR7066
・発行会社(調査会社):Technavio
・発行日:2015年9月9日
・ページ数:70
・レポート言語:英語
・レポート形式:pdf
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、子宮頸がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、子宮頸がん治療薬の世界市場規模及び予測、種類別分析、用途別分析、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About cervical cancer
Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world’s fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.

Technavio’s analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.

[Covered in this report]
The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.

Technavio’s report, Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
Americas
APAC
EMEA

[Key vendors]
F. Hoffmann-La Roche
GlaxoSmithKline
Merck

[Other prominent vendors]
Advaxis Immunotherapies
Bionor Pharma
Dendreon Corporation
Inovio Pharmaceuticals
ISA Pharmaceuticals
Otsuka Pharmaceuticals
Profectus Biosciences
Virometix
Zeria Pharmaceuticals

[Market Driver]
Increase in incidence rate
For a full, detailed list, view our report

[Market challenge]
Adverse effects of drugs and vaccines
For a full, detailed list, view our report

[Market trend]
Patient assistance programs
For a full, detailed list, view our report

[Key questions answered in this report]
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

【レポートの目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Screening
Diagnosis
Staging
Treatment
Epidemiology

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Market segmentation by application
Global prophylactic vaccines market
Global therapeutic drugs market

PART 08: Market segmentation by type of therapy
Global cervical cancer therapeutics market by type of therapy
Chemotherapy
Targeted therapy
HPV vaccines

PART 09: Geographical segmentation

PART 10: Key brand analysis
Comparative study between Gardasil, Gardasil 9, and Cervarix

PART 11: Pipeline portfolio

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape
Competitive scenario
Market analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
GSK
F. Hoffmann-La Roche
Merck

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Risk factors for cervical cancer
Exhibit 02: Screening tests for cervical cancer
Exhibit 03: Diagnostic tests for cervical cancer
Exhibit 04: FIGO staging for cervical cancer
Exhibit 05: Management of cervical cancer
Exhibit 06: Chemotherapy for treatment of cervical cancer
Exhibit 07: Cervical cancer treatment algorithm
Exhibit 08: Countries with highest cervical cancer rates
Exhibit 09: Cervical cancer deaths by age group in the US 2008-2012
Exhibit 10: Age-specific incidence rates of cervical cancer in the US by race 2008-2012
Exhibit 11: Age-specific mortality rates of cervical cancer of women in the US by race 2008-2012
Exhibit 12: Mortality rates of cervical cancer of women in the US by race 2008-2012
Exhibit 13: Average number of cervical cancer deaths in EU 2010-2012
Exhibit 14: Cervical cancer incidence and mortality rates in EU 2007-2011
Exhibit 15: Global cervical cancer therapeutics market 2014-2019 ($ billions)
Exhibit 16: Global cervical cancer therapeutics market segmentation by application
Exhibit 17: Global prophylactic vaccines market 2014-2019 ($ millions)
Exhibit 18: Global therapeutic drugs market 2014-2019 ($ millions)
Exhibit 19: Segmentation of global cervical cancer therapeutics market 2014
Exhibit 20: Global cervical cancer therapeutics market by type of therapy
Exhibit 21: Segmentation of global cervical cancer therapeutics market by region 2014
Exhibit 22: Global cervical cancer vaccines market: Comparison of major brands
Exhibit 23: Gardasil, Gardasil 9, and Cervarix: A comparative study
Exhibit 24: Key late-stage HPV vaccines for cervical cancer
Exhibit 25: Drivers of global cervical cancer therapeutics market
Exhibit 26: Impact of drivers
Exhibit 27: Challenges of global cervical cancer therapeutics market
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Trends of global cervical cancer therapeutics market
Exhibit 30: Gardasil: Global revenue and growth rate 2011-2014
Exhibit 31: Merck: Key takeaways
Exhibit 32: Cervarix: Global revenue and growth rate 2012-2014
Exhibit 33: GSK: Key takeaways
Exhibit 34: F. Hoffman-La Roche: Key takeaways



【掲載企業】

F. Hoffmann-La Roche, GlaxoSmithKline, Merck ,Advaxis Immunotherapies, Bionor Pharma, Dendreon Corporation, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceuticals, Profectus Biosciences, Virometix, Zeria Pharmaceuticals

【レポートのキーワード】

子宮頸がん治療薬、予防ワクチン、医薬品、化学療法、標的治療、子宮頸がんワクチン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[子宮頸がん治療薬の世界市場2015-2019] (コード:IRTNTR7066)販売に関する免責事項を必ずご確認ください。
★調査レポート[子宮頸がん治療薬の世界市場2015-2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆